Stromedix inc
WebStromedix [Recruiting] Cambridge, Massachusetts, United States, 02141: IPDSharing. Plan to Share IPD: References. Citations: Links: Available IPD/Information: Scroll up to access the controls Scroll to the Study top. U.S. National Library of Medicine ... WebApr 6, 2009 · May 20, 2011 updated by: Stromedix, Inc. Randomized Double-Blind, Placebo-Controlled, Single and Multiple Dose, Dose-Escalation Study of STX 100 in Renal Transplant Patients With Biopsy Proven Interstitial Fibrosis and Tubular Atrophy (IF/TA)
Stromedix inc
Did you know?
WebFeb 14, 2012 · Stromedix is a privately held biotechnology company based in Cambridge, Massachusetts, focused on innovative therapies for fibrosis and organ failure. … WebJun 3, 2011 · This study was previously posted by Stromedix, Inc. In April, 2014, sponsorship of the trial was transferred to Biogen. The study drug name was changed from STX-100 to BG00011 and the study number was changed from STX-003 to 203PF201, to align with sponsor conventions.
WebTim Rice - Director Program Leadership and Management - Biogen Idec LinkedIn Tim Rice Director Program Management at Stromedix, Inc. Cambridge, Massachusetts, United States 67 connections... WebFeb 14, 2012 · Stromedix is a privately held biotechnology company based in Cambridge, Massachusetts, focused on innovative therapies for fibrosis and organ failure. …
WebPrior to founding Stromedix in 2006, Mike served as Executive Vice President, Research at Biogen Idec, with responsibility for the company’s discovery research activities in Cambridge and San Diego. From 1994 to 1999, Mike was at ARIAD Pharmaceuticals, where he was Executive Vice President and Chief Scientific Officer. ... WebSTROMEDIX, INC. is a Delaware Corporation filed on June 8, 2006. The company's File Number is listed as 4172146. The Registered Agent on file for this company is …
WebBrand New. Approach to Medicine. A worry-free process customized just for you. Combining Pain Management and Regenerative Medicine. For Orthopedic, Neurodegenerative, …
WebFeb 14, 2012 · Biogen Idec Inc. said Tuesday it will pay $75 million upfront and as much as $487.5 million in future payments to acquire closely held biotechnology company Stromedix Inc., which is working on a ... the arc of ectWebComing off a year in which its earnings topped $5 billion, drugmaker Biogen Idec Inc. has struck a deal to pay $75 million — and possibly much more — for privately owned Stromedix Inc. and its ... the arc of history mlkWebThe Weston, MA-based biotech power has bought nearby Stromedix, whose lead fibrosis drug STX-100 was licensed from Biogen. The deal Biogen Idec ($BIIB) has scooped up a … the ghost of christmas present disneyWebSep 17, 2024 · The company has discontinued a Phase II trial for BG00011, which was acquired in its 2012 Stromedix purchase, due to safety issues. the arc of howard county jobsWebFounder of Infinity Pharmaceuticals, Inc., DNX Corp., Biotechnology Innovation Organization and Shoreline Biosciences, Inc., Steven H. Holtzman is an American entrepreneur and businessperson who has been at the head of 6 different companies and currently is Chairman of Camp4 Therapeutics Corp., Chairman for Hangzhou Qihan Biotechnology Co. … the arc of hawaiiWebCloud-Based Solutions for Healthcare and Insurance. Stradix is a leader in the independent medical review and claims management process and offers a variety of services to meet … the ghost of christmas to comeWebMichael Dambach occupies the position of Treasurer & Vice President for Biogen, Inc. and Treasurer, Director & Vice President at Stromedix, Inc. (a subsidiary of Biogen, Inc.). In the past he occupied the position of Treasurer & Director at Bioverativ Therapeutics, Inc. Current positions of Michael Dambach. the ghost of christmas present movie